BIOSTEM TECHNOLOGIES
BSEM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BSEM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BSEM
BioStem Technologies is a regenerative medicine company focused on developing and commercializing perinatal tissue allografts for wound care and surgical applications, leveraging a diversified site-of-care platform and vertically integrated manufacturing.
Key risk: Reimbursement and pricing risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for BIOSTEM TECHNOLOGIES.
BioStem Technologies is a regenerative medicine company focused on developing and commercializing perinatal tissue allografts for wound care and surgical applications, leveraging a diversified site-of-care platform and vertically integrated manufacturing.
- BioStem offers dry and cryopreserved allografts used as protective barriers to support natural healing in wound care and surgical settings [sec · filed 2026-07-29].
- The company acquired assets from BioTissue in January 2026, including the Neox® and Clarix® trademarks, to expand into hospital and ambulatory surgical center settings [sec · filed 2026-07-29].
- As of June 30, 2026, BioStem reported cash & equivalents of $7.0M, total revenue of $7.9M, and a net loss of -$9.0M [sec].
- The company incurred a net loss of $6.6 million for the year ended December 31, 2025, and had an accumulated deficit of $21.2 million as of that date [sec · filed 2026-07-29].
- BioStem is investing in three ongoing clinical trials (BRAC DFU, BRA DFU, BRAC VLU) with R&D expenses of $7.1 million in 2025 [sec · filed 2026-07-29].
What works
- Diversified site-of-care platform spanning physician offices, hospitals, and ASCs following the BioTissue acquisition [sec · filed 2026-07-29].
- Comprehensive portfolio of dry, cryopreserved, and shelf-stable perinatal tissue allografts addressing a broad range of clinical indications [sec · filed 2026-07-29].
- Vertically integrated manufacturing facility in Pompano Beach, Florida, which is FDA-registered and AATB-accredited, offering potential for margin expansion [sec · filed 2026-07-29].
- Growing body of clinical evidence, including randomized controlled trials and published studies, supporting product differentiation and physician adoption [sec · filed 2026-07-29].
What to weigh
- The company expects to incur net losses and negative cash flows from operations for at least the next twelve months due to CMS pricing changes and contractual obligations [sec · filed 2026-07-29].
- Accumulated deficit of $29.99 million as of March 31, 2026, reflecting ongoing losses [sec · filed 2026-07-29].
- Dependence on reimbursement policies and payer coverage, which can be subject to change and affect product utilization [sec · filed 2026-07-29].
- Significant ongoing expenses for sales expansion, R&D, and public company infrastructure may delay profitability [sec · filed 2026-07-29].
From the filings
Quoted directly from source documents.
BioStem's products are supported by clinical data including randomized controlled trials.
“Our products are supported by a growing body of clinical and scientific data, including randomized controlled trials and published retrospective studies.”
SEC filings · July 29, 2026
The company expects net losses and negative cash flows for at least the next twelve months.
“The Company expects to incur net losses and negative cash flows from operations for at least the next twelve months due to recent changes to product pricing determined by CMS and has contractual obligations over the next twelve months related to the BioTissue acquisition and an existing loan.”
SEC filings · July 29, 2026
BioStem acquired BioTissue assets to expand into hospital and surgical settings.
“On January 21, 2026, we expanded our portfolio through the purchase and licensing of certain assets from BioTissue's surgical and wound care business.”
SEC filings · July 29, 2026
The company has an accumulated deficit of $29.99 million as of March 31, 2026.
“had an accumulated deficit of $29,994,021 as of March 31, 2026.”
SEC filings · July 29, 2026
Risks & what to watch (4)›
Key risks
- Reimbursement and pricing risk — Changes to CMS pricing and payer coverage could reduce revenue and profitability [sec · filed 2026-07-29].
- Ongoing net losses — The company expects continued net losses and negative cash flows for at least the next twelve months [sec · filed 2026-07-29].
- Clinical trial execution — R&D expenses for three ongoing trials may not lead to successful outcomes or market adoption [sec · filed 2026-07-29].
- Integration of BioTissue assets — Acquisition integration may incur unexpected costs or fail to achieve expected synergies [sec · filed 2026-07-29].
What to watch
- Progress and results of the three ongoing clinical trials (BRAC DFU, BRA DFU, BRAC VLU) [sec · filed 2026-07-29].
- Revenue growth and margin trends following the BioTissue acquisition and expansion into hospital/ASC settings [sec · filed 2026-07-29].
- Payer coverage decisions and CMS reimbursement updates affecting product utilization [sec · filed 2026-07-29].
- Cash runway and ability to secure additional financing given expected near-term losses [sec · filed 2026-07-29].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run BIOSTEM TECHNOLOGIES through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOSTEM TECHNOLOGIES facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.5 months
D/E 0.77 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BIOSTEM TECHNOLOGIES?
BioStem Technologies is a regenerative medicine company focused on developing and commercializing perinatal tissue allografts for wound care and surgical applications, leveraging a diversified site-of-care platform and vertically integrated manufacturing.
Who is the CEO of BIOSTEM TECHNOLOGIES?
Mr. Jason V. Matuszewski is the chief executive officer of BIOSTEM TECHNOLOGIES (BSEM).
Where is BIOSTEM TECHNOLOGIES headquartered?
BIOSTEM TECHNOLOGIES (BSEM) is headquartered in Fort Lauderdale, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.